false 0001583648 0001583648 2025-03-04 2025-03-04
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 

 
FORM 8-K
 

 
CURRENT REPORT
 
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): March 4, 2025
 

 
PALVELLA THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
 

 
Nevada
001-37471
30-0784346
(State or other jurisdiction of
incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
 
125 Strafford Ave, Suite 360
 
Wayne, Pennsylvania
19087
(Address of principal executive offices)
(Zip Code)
 
Registrant’s telephone number, including area code: (484) 253-1461
 
 
(Former name or former address, if changed since last report.)
 

 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
 
Trading Symbol(s)
 
Name of each exchange on which registered
Common stock, $0.001 par value per share
 
PVLA
 
The Nasdaq Capital Market
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 

 
Item 7.01
Regulation FD Disclosure.
 
On March 4, 2025, Palvella Therapeutics, Inc. (the “Company”) posted a corporate presentation to its website, which representatives of the Company will use in various meetings with investors from time to time. A copy of the presentation is attached hereto as Exhibit 99.1, and incorporated herein by reference.
 
The information furnished pursuant to Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
 
 
Item 9.01
Financial Statements and Exhibits.
 
(d) Exhibits
 
Exhibit No.
 
Document
99.1
 
104
 
Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
*Furnished herewith
 
 

 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
  PALVELLA THERAPEUTICS, INC. 
     
     
Date: March 4, 2025
By:
/s/ Matthew Korenberg
   
Matthew Korenberg
   
Chief Financial Officer
 
 

Exhibit 99.1

 

 

slide01.jpg

 

 

 

 
slide02.jpg

 

 

 
slide03.jpg

 

 

 
slide04.jpg

 

 

 
slide05.jpg

 

 

 
slide06.jpg

 

 

 
slide07.jpg

 

 

 
slide08.jpg

 

 

 
slide09.jpg

 

 

 
slide10.jpg

 

 

 
slide11.jpg

 

 

 
slide12.jpg

 

 

 
slide13.jpg

 

 

 
slide14.jpg

 

 

 
slide15.jpg

 

 

 
slide16.jpg

 

 

 
slide17.jpg

 

 

 
slide18.jpg

 

 

 
slide19.jpg

 

 

 
slide20.jpg

 

 

 
slide21.jpg

 

 

 
slide22.jpg

 

 

 
slide23.jpg

 

 

 
slide24.jpg

 

 

 
slide25.jpg

 

 

 
slide26.jpg

 

 

 
slide27.jpg

 

 

 
slide28.jpg

 

 

 
slide29.jpg

 

 

 
slide30.jpg

 

 

 
slide31.jpg

 

 

 
slide32.jpg

 

 

 
slide33.jpg

 

 

 
slide34.jpg

 

 

 
slide35.jpg

 

 

 
slide36.jpg

 

 

 
slide37.jpg

 

 
v3.25.0.1
Document And Entity Information
Mar. 04, 2025
Document Information [Line Items]  
Entity, Registrant Name PALVELLA THERAPEUTICS, INC.
Document, Type 8-K
Document, Period End Date Mar. 04, 2025
Entity, Incorporation, State or Country Code NV
Entity, File Number 001-37471
Entity, Tax Identification Number 30-0784346
Entity, Address, Address Line One 125 Strafford Ave, Suite 360
Entity, Address, City or Town Wayne
Entity, Address, State or Province PA
Entity, Address, Postal Zip Code 19087
City Area Code 484
Local Phone Number 253-1461
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock
Trading Symbol PVLA
Security Exchange Name NASDAQ
Entity, Emerging Growth Company false
Amendment Flag false
Entity, Central Index Key 0001583648

Palvella Therapeutics (NASDAQ:PVLA)
Graphique Historique de l'Action
De Fév 2025 à Mar 2025 Plus de graphiques de la Bourse Palvella Therapeutics
Palvella Therapeutics (NASDAQ:PVLA)
Graphique Historique de l'Action
De Mar 2024 à Mar 2025 Plus de graphiques de la Bourse Palvella Therapeutics